Link to Full Article Favourable pharmacokinetic/pharmacodynamic profile compared to current best in class insulin treatment Cambridge, UK., 5th December 2019: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247. […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-12-05 02:59:272019-12-30 03:01:17ARECOR ANNOUNCES POSITIVE HEADLINE RESULTS FOR THE FIRST PHASE I CLINICAL TRIAL OF AT247, A NOVEL ULTRA RAPID ACTING FORMULATION OF INSULIN
Link to Full Article Cambridge, United Kingdom – 3rd December, 2019 – Congenica Ltd, a digital health company enabling rapid analysis of complex genomic data to improve disease characterization and diagnosis, has announced the publication of a new study on the re-annotation of developmental and epileptic encephalopathy-associated genes with significant clinical implications. Developmental and epileptic encephalopathies are a group of rare, […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-12-03 01:43:562020-01-07 00:17:36Re-annotation of 191 developmental and epileptic encephalopathy-associated genes unmasks de novo variants in SCN1A
Link to Full Article Experienced pharmaceutical executive and medical director with expertise in anti-infective drug development and in-licensing Brighton, United Kingdom – 2 December 2019 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs that address clear commercial opportunities and also address the global problem of […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-12-02 01:47:172020-01-03 01:51:14Destiny Pharma appoints Dr Debra Barker as Non-Executive Director
Link to Full Article Liam is Head of Technology Transfer at The Science and Technology Facilities Council (STFC), part of UK Research and Innovation. STFC established The Electrospinning Company in 2010 and have invested and supported the Company since then. After completing his PhD, Liam co-founded and led a company to target an opportunity to […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-12-01 01:53:222020-01-03 01:54:21Dr Liam Brennan has joined the Board as the STFC Investor Director, replacing Dr Kate Ronayne.
Link to Full Article AVITA Medical secures option for exclusive licensing of emerging technologies Preclinical research will pair AVITA Medical’s Spray-On Skin™ Cells technology and expertise with the Gates Center’s patent pending combined reprogramming and gene editing methodology Valencia, Calif., USA, Melbourne, Australia, and Aurora, Colo., USA, 25 November 2019 — AVITA Medical (ASX: AVH, […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-11-25 00:58:342020-01-03 01:31:53AVITA Medical and the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus Enter into Collaboration to Explore Potential Spray-On Treatment of Genetically Modified Cells for Epidermolysis Bullosa
Link to Full Article • Appointment Enhances Executive Leadership Team as AVITA Medical Broadens Access to Investors and Continues Growth Trajectory • Interim CFO Tim Rooney Remains with Company as Chief Administrative Officer Valencia, Calif., USA, and Melbourne, Australia, 18 November 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-11-18 00:50:582020-01-03 01:31:21AVITA Medical Names David McIntyre as Chief Financial Officer
Link to Full Article Valencia, Calif., USA, and Melbourne, Australia, 13 November 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today an institutional placement of A$120.0 million (Institutional Placement) to fund pipeline development of new indications, […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-11-13 00:37:092020-01-03 01:32:45AVITA Medical Announces Institutional Placement of A$120.0 Million to Support Commercial Growth and Pipeline Development
Link to Full Article MARINA DEL REY, Calif., Nov. 12, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced third quarter results and provided a corporate and clinical update. Key Third Quarter and Subsequent Period Highlights: Announced development of […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-11-12 03:02:442019-12-30 03:03:57Armata Pharmaceuticals Announces Third Quarter Results and Provides Corporate and Clinical Update
Link to Full Article Congenica platform provides variant review and assessment to support conclusive diagnoses for patients with complex and commonly misdiagnosed bleeding disorders in a large multicenter genomic study. MYH9-related disorder (MYH9-RD) is a complex condition that can have many signs and symptoms, including bleeding problems, hearing loss, kidney disease, and cataracts. The complexity […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-11-12 01:41:502020-01-03 01:43:40A fast and reliable method to reach a conclusive diagnosis of MYH9-related disorder
Link to Full Article Valencia, Calif., USA, and Melbourne, Australia, 8 November 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today that the company will be added to the S&P/ASX 200 index, effective upon market open […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-11-09 00:30:252020-01-03 01:33:47AVITA Medical Added to S&P/ASX 200 Index
ARECOR ANNOUNCES POSITIVE HEADLINE RESULTS FOR THE FIRST PHASE I CLINICAL TRIAL OF AT247, A NOVEL ULTRA RAPID ACTING FORMULATION OF INSULIN
/in ArecorLink to Full Article Favourable pharmacokinetic/pharmacodynamic profile compared to current best in class insulin treatment Cambridge, UK., 5th December 2019: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247. […]
Re-annotation of 191 developmental and epileptic encephalopathy-associated genes unmasks de novo variants in SCN1A
/in Congenica, UncategorisedLink to Full Article Cambridge, United Kingdom – 3rd December, 2019 – Congenica Ltd, a digital health company enabling rapid analysis of complex genomic data to improve disease characterization and diagnosis, has announced the publication of a new study on the re-annotation of developmental and epileptic encephalopathy-associated genes with significant clinical implications. Developmental and epileptic encephalopathies are a group of rare, […]
Destiny Pharma appoints Dr Debra Barker as Non-Executive Director
/in Destiny PharmaLink to Full Article Experienced pharmaceutical executive and medical director with expertise in anti-infective drug development and in-licensing Brighton, United Kingdom – 2 December 2019 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs that address clear commercial opportunities and also address the global problem of […]
Dr Liam Brennan has joined the Board as the STFC Investor Director, replacing Dr Kate Ronayne.
/in ElectrospinningLink to Full Article Liam is Head of Technology Transfer at The Science and Technology Facilities Council (STFC), part of UK Research and Innovation. STFC established The Electrospinning Company in 2010 and have invested and supported the Company since then. After completing his PhD, Liam co-founded and led a company to target an opportunity to […]
AVITA Medical and the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus Enter into Collaboration to Explore Potential Spray-On Treatment of Genetically Modified Cells for Epidermolysis Bullosa
/in Avita MedicalLink to Full Article AVITA Medical secures option for exclusive licensing of emerging technologies Preclinical research will pair AVITA Medical’s Spray-On Skin™ Cells technology and expertise with the Gates Center’s patent pending combined reprogramming and gene editing methodology Valencia, Calif., USA, Melbourne, Australia, and Aurora, Colo., USA, 25 November 2019 — AVITA Medical (ASX: AVH, […]
AVITA Medical Names David McIntyre as Chief Financial Officer
/in Avita MedicalLink to Full Article • Appointment Enhances Executive Leadership Team as AVITA Medical Broadens Access to Investors and Continues Growth Trajectory • Interim CFO Tim Rooney Remains with Company as Chief Administrative Officer Valencia, Calif., USA, and Melbourne, Australia, 18 November 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a […]
AVITA Medical Announces Institutional Placement of A$120.0 Million to Support Commercial Growth and Pipeline Development
/in Avita MedicalLink to Full Article Valencia, Calif., USA, and Melbourne, Australia, 13 November 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today an institutional placement of A$120.0 million (Institutional Placement) to fund pipeline development of new indications, […]
Armata Pharmaceuticals Announces Third Quarter Results and Provides Corporate and Clinical Update
/in Armata PharmaceuticalsLink to Full Article MARINA DEL REY, Calif., Nov. 12, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced third quarter results and provided a corporate and clinical update. Key Third Quarter and Subsequent Period Highlights: Announced development of […]
A fast and reliable method to reach a conclusive diagnosis of MYH9-related disorder
/in CongenicaLink to Full Article Congenica platform provides variant review and assessment to support conclusive diagnoses for patients with complex and commonly misdiagnosed bleeding disorders in a large multicenter genomic study. MYH9-related disorder (MYH9-RD) is a complex condition that can have many signs and symptoms, including bleeding problems, hearing loss, kidney disease, and cataracts. The complexity […]
AVITA Medical Added to S&P/ASX 200 Index
/in Avita MedicalLink to Full Article Valencia, Calif., USA, and Melbourne, Australia, 8 November 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today that the company will be added to the S&P/ASX 200 index, effective upon market open […]